Drug Profile


Alternative Names: Erismodegib; LDE-225; NVP-LDE-225; Odomzo

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Novartis; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford University; University of Alabama at Birmingham
  • Class Antineoplastics; Biphenyl compounds; Morpholines; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Haematological malignancies; Medulloblastoma; Multiple myeloma; Solid tumours
  • Phase I/II Myelofibrosis; Ovarian cancer; Pancreatic cancer
  • Phase I Breast cancer; Chronic myeloid leukaemia; Graft-versus-host disease; Hepatocellular carcinoma; Myelodysplastic syndromes; Oesophageal cancer; Prostate cancer
  • Discontinued Basal cell nevus syndrome

Most Recent Events

  • 22 Dec 2016 Sun Pharma plans to acquire Sonidegib (Odomzo®) worldwide
  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Novartis and Massachusetts General Hospital terminates phase I trial in Graft-versus-host disease in USA (NCT02086513)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top